Skip to main content

Day: April 22, 2021

Quarterly Information at 31 March 2021

Rueil Malmaison, 22 April 2021 QUARTERLY INFORMATION AT 31 MARCH 2021Revenue: €10.2 billion, up 5% compared with the first quarter of 2020VINCI Energies: up 7% VINCI Construction1 (including Eurovia): up 10% VINCI Autoroutes: stable revenue VINCI Airports: down 70% as a result of the global Covid-19 crisisOrder book up 21% Net financial debt sharply down €3.5 billion compared with 31 March 2020 and very strong liquidity 2021 outlook unchangedConsolidated revenue            First quarter 2021/2020change 2021/2019 change(in € millions) 2021 2020 Actual Like-for-like2 ActualConcessions 1,325 1,704 -22.2% -21.4% -20.2%VINCI Autoroutes 1,108 1,112 -0.4% -0.4% -5.3%VINCI Airports 155 521 -70.1% -69.4% -62.9%Other concessions3 62 71 -13.2% -6.5% -13.5%VINCI Energies 3,405 3,172 +7.3% +6.0% +12.8%VINCI Construction 5,255 4,777 +10.0% +11.2% +6.1%VINCI...

Continue reading

Artefact : Forte progression des résultats 2020 – Excellentes perspectives de croissance et de rentabilité

Forte progression des résultats 2020Excellentes perspectives de croissance et de rentabilitéMarge brute 2020 : 70,3 M€, +10% en proforma EBITDAr12020 : 13,9 M€ soit 20% de la marge brute Résultat net ajusté2: 8,9 M€ Marge brute T1 2021 : 20,0 M€, +12% à taux constants Excellentes perspectives de développement et de rentabilité   Accélération du développement international avec l’ouverture d’une filiale aux Etats-Unis Objectifs 2021 : marge brute supérieure à 80 M€ et marge d’EBITDAr comprise entre 22% et 25% Objectifs 2025 : croissance annuelle organique comprise entre 15% et 20%et maintien de la marge d’EBITDAr entre 22% et 25%Paris, le 22 avril 2021 – 17h45 CEST – Artefact (FR0000079683 – ALATF – éligible PEA-PME), expert dans la transformation data et le marketing digital auprès des grandes marques, annonce aujourd’hui...

Continue reading

Artefact: Strong improvement in 2020 results – Solid growth and profitability outlooks

Strong improvement in 2020 resultsSolid growth and profitability outlooks2020 gross margin: €70.3m, +10% pro forma 2020 EBITDAr1: €13.9m, or 20% of the gross margin Adjusted net profit2: €8.9m Q1 2021 gross margin: €20.0m, +12% at constant currency rate Solid growth and profitability outlooks Acceleration in international development with the opening of US office 2021 targets: gross margin above €80m and EBITDAr margin between 22% and 25% 2025 targets: annual organic growth from 15% to 20%,EBITDAr margin maintained at 22% – 25%Paris, April 22, 2021 – 5:45 pm CEST – Artefact (FR0000079683 – ALATF – eligible for PEA-PME equity savings plans), an expert in data transformation and digital marketing for major brands, today announced its consolidated results for 2020 financial year and published its gross margin for the first...

Continue reading

INFORMATION TRIMESTRIELLE AU 31 MARS 2021

Rueil-Malmaison, le 22 avril 2021 INFORMATION TRIMESTRIELLE AU 31 MARS 2021Chiffre d’affaires : 10,2 milliards d’euros, en progression de 5 % par rapport au 1er trimestre 2020VINCI Energies : +7 % VINCI Construction1 (y compris Eurovia) : +10 % VINCI Autoroutes : chiffre d’affaires stable VINCI Airports : forte baisse (-70 %), conséquence de la crise sanitaire mondialeCarnet de commandes en hausse (+21 %) Diminution significative de l’endettement financier net sur un an (-3,5 milliards d’euros) – très haut niveau de liquidité Perspectives 2021 inchangéesChiffre d’affaires consolidé            1er trimestre Variation2021/2020 Variation 2021/2019En millions d’euros 2021 2020 Réelle Comparable2 RéelleConcessions 1 325 1 704 -22,2 % -21,4 % -20,2 %VINCI Autoroutes 1 108 1 112 -0,4 % -0,4 % -5,3 %VINCI Airports 155 521 -70,1...

Continue reading

Palmetto MolDx Issues Foundational Coverage for Molecular Testing in Solid Organ Allograft Rejection

SOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today that Palmetto MolDx finalized the local coverage determination “Molecular Testing for Solid Organ Allograft Rejection,” reaffirming coverage and patient access to transplant testing services. Medicare coverage for CareDx services remains unchanged under the new foundational coverage policy. This policy provides greater access to care and establishes a faster path to coverage of other solid organs in transplantation. “We applaud Palmetto MolDx in this policy to support the field of transplant,” said Reg Seeto, President and CEO...

Continue reading

WRAP Awarded ISO 9001:2015 Certification Marking Compliance with International Quality Standards

TEMPE, Ariz., April 22, 2021 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP), a global leader in innovative public safety technologies and services, announced today that it has earned ISO 9001:2015 certification for its Quality Management System. The internationally recognized standard, developed and published by the International Organization for Standardization (ISO), is based on several quality management principles, including a strong customer focus, the motivation and implication of top management, the process approach, and continual improvement. The scope of WRAP’s certification includes design, manufacturing, assembly, training, sales and service. “Achieving ISO 9001:2015 certification demonstrates WRAP’s commitment to meeting the highest international standards...

Continue reading

Investeringsselskabet Artha Optimum A/S – gennemførelse af aktiesplit

Selskabsmeddelelse nr. 7, 2021 Holte, 22. april 2021 Gennemførelse af aktiesplit Beslutning om gennemførelse af aktiesplit Investeringsselskabet Artha Optimum A/S På den ordinære generalforsamling i Investeringsselskabet Artha Optimum A/S afholdt dags dato blev det godkendt at gennemføre en ændring af selskabets aktiers stykstørrelse fra DKK 15.000 til DKK 1.500 eller multipla heraf. Aktiesplittet gennemføres således i forholdet 1:10.  Ved aktiesplittet vil hver eksisterende aktie på nominelt DKK 15.000 blive opdelt i ti (10) nye aktier på nominelt DKK 1.500. Selskabets nominelle aktiekapital på nominelt DKK 728.460.000 vil fremadrettet være opdelt på 485.640 aktier á nominelt DKK 1.500, som hver giver én stemme. Planen for gennemførelse af aktiesplittet er som følger: Mandag den 3. maj 2021Sidste handelsdag på Nasdaq Copenhagen via Fondskode...

Continue reading

Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test

 Todos plans to commercialize Videssa in late 2021 to reduce unnecessary biopsies in the $7.19 billion mammogram naïve market and integrate it into its TBIA Platform Provista Diagnostics’ testing lab in the Atlanta, Georgia area is currently performing COVID-19 testing, that will be automated to significantly increase processing capacityTodos expects to employ testing methodologies to expand Provista’s capabilities regarding COVID variant identificationNEW YORK, NY, and REHOVAT, ISRAEL, April 22, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has acquired Provista Diagnostics, Inc. Provista is a medical diagnostics company based in Alpharetta, Georgia that owns the intellectual property rights...

Continue reading

AUGA group, AB Notification of transactions by persons discharging managerial responsibilities

AUGA group, AB (Company) received notifications of transactions by persons discharging managerial responsibilities (attached). Notifications have been received in respect of execution of option transactions under the programme whereunder the Company shall grant its shares in the future to the employees and members of management of the Company and its subsidiaries (Employees). Under such option agreements, after 3 years Employees shall be entitled to elect whether to receive from the Company the shares specified in their option agreements. Shares shall be granted to the Employees free of charge (i.e. for EUR 0), shares shall be paid up from the company’s reserve formed for granting the shares to employees. CEOKestutis Juscius+370 5 233 5340 Attachments

Continue reading

AUGA group, AB pranešimai apie vadovaujančias pareigas einančių asmenų sandorius

AUGA group, AB (Bendrovė) gavo pranešimus apie vadovaujančias pareigas einančių asmenų sandorius (pridedami). Sandoriai, dėl kurių gauti pranešimai, yra pasirinkimo (opcionų) sandoriai  pagal programą dėl Bendrovės akcijų suteikimo Bendrovės ir jos dukterinių įmonių darbuotojams ir valdymo organų nariams (Darbuotojai). Pagal šias opcionų sutartis Darbuotojai turės teisę ne anksčiau kaip po 3 metų pasirinkti, ar gauti iš Bendrovės sutartyje nustatytas akcijas. Akcijos Darbuotojams bus suteikiamos neatlygintinai (t. y. už 0 EUR), apmokamos iš Bendrovės suformuoto rezervo akcijoms suteikti. Generalinis direktoriusKęstutis Juščius+370 5 233 5340 Priedai

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.